Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-11-27
2007-11-27
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S612000
Reexamination Certificate
active
10666191
ABSTRACT:
The present invention relates to novel estrogen-related steroidal quinols and their use as drugs for estrogen replacement therapy. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues, bone, in the cardiovascular system, and in the CNS (central nervous system) with only a slight estrogenic action or no estrogenic action in the uterus. The compounds are suitable for the production of pharmaceutical agents for use in numerous indications (for example, estrogen replacement therapy, prevention and treatment of osteoporosis).
REFERENCES:
patent: 2910486 (1959-10-01), Jiu
patent: 2950291 (1960-08-01), Jiu
patent: 5108996 (1992-04-01), Claussner et al.
patent: 5395831 (1995-03-01), Gemmill, Jr. et al.
patent: 5552395 (1996-09-01), Gemmill, Jr. et al.
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5891878 (1999-04-01), Beasley et al.
patent: 6197833 (2001-03-01), Simpkins et al.
patent: 6319914 (2001-11-01), Simpkins et al.
patent: 6583170 (2003-06-01), Pickar et al.
patent: 2003/0050295 (2003-03-01), Pang
patent: 2003/0105167 (2003-06-01), Dykens
patent: 2004/0214806 (2004-10-01), Pang
patent: WO 03/084978 (2003-10-01), None
Numazawa et al., Chem. Pharm. Bull., 37(8), pp. 2058-2062, 1989.
Ohe et al., Drug Metabolism and Disposition, 28(2), pp. 110-112, 2000.
Nali et al., “The bis(salicylaldehyde)ethylenediiminocobalt (II) catalyzed C-10 oxygenation of estrogens.”, J. of Molecular Catalysis, vol. 41(3), pp. 349-354, 1987, English Abstract only.
Sedee et al., “A synthesis for p-quinol compounds from phenols fused with other saturated rings.”, Tetrahedron Letters, vol. 24(51), pp. 5779-5780, 1983.
Breuer, H. and Koster, G. (1974) “Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level.”Journal of Steroid Biochemistry. vol. 5, pp. 961-967.
Galdecki, Z., P. et al. (1987) “Structure of 2,4-Dibromo-10β, 17β-dihydroxy-1,4-estradien-3-one”Acta Cryst. vol. c43, pp. 967-968.
Hiemke, C. et al. (1992) “Actions of Sex Hormones on the Brain.”Prog. Neuro-Psychopharmacol.&Biol.Psychiat. vol. 16, pp. 377-388.
Kupfer, Rene, Long Yu Liu, Alban J. Allentoff, John A. Thompson (2001) “Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site”Biochemistry40:11490-11501.
Liang, Y. et al. (2001) “Membrane fluidity effects of estratrienes.”Brain Research Bulletin. vol. 54, No. 6, pp. 661-668.
McCullough, Louise D. and Patricia D. Hurn (Jul. 2003) “Estrogen and Ischemic Neuroprotection: an integrated view”Trends in Endocrinology and Metabolism14(5):228-235.
Milic, D. et al.(1999) “X-Ray Crystal Structure of 10β-Hydroxy-4β,5β-expoxyerstr-1-en-3,17-dione and Antitumor Activity of its Congeners”Molecules, vol. 4, pp. 338-352.
Milic, D. et al. (1997) “The Synthesis and Biological Evaluation of A-Ring Substituted Steroidalp-Quinones”Tetrahedron, vol. 53, No. 41, pp. 14073-14084.
Milic, D. et al. (1997) “Structure and Reactivity of Steroidal Quinones”J. Serb. Chem. Soc., vol. 62, No. 9, pp. 755-768.
Nilsen, J. and Brinton, D. (2003) “Divergent Impact of Progesterone and Medroxyprogesterone Acetate (Provera) on Nuclear Mitogen-activated Protein Kinase Signaling.” vol. 100, No. 18, pp. 10506-10511.
Nilsen, Jon and Roberta Diaz Brinton (Jan. 2002) “Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate”Endocrinology143(1):205-212.
Numazawa, Mitsuteru, Kumiko Hoshi, Katsuhiko Kimura (1989) “Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nore Steroids”Chem. Pharm. Bull. 37(8):2058-2062.
Ohe, Tomoyuki, Masaaki Hirobe, Tadahiko Mashino (2000) “Novel Metabolic Pathway of Estrone and 17β-Estradiol Catalyzed by Cytochrome P-450”Drug Metabolism and Disposition28(2):110-112.
Prokai, K.et al. (2003) “Modifying Peptide Properties by Prodrug Design For Enhanced Transport into CNS.”Progress in Drug Research, vol. 61, pp. 158-188.
Prokai, L. et al. (2003) “Quinol-based Cyclic Antioxidant Mechanism in Estrogen Neuroprotection”PNAS, vol. 100 No. 2, pp. 11741-11746.
Prokai, L. et al. (2003) “Short Communication: Quinol-Based Metabolic Cycle For Estrogens in Rat Liver Microsomes”Drug and Metabolism and Disposition, vol. 31, No. 6, pp. 701-704.
Prokai, L. et al. (2001) “Synthesis and Biological Evaluation of 17β-Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress”J. Med. Chem., vol. 44, pp. 110-114.
Prokai, L., et al. (2000) “Targeting Drugs to the Brain by Redox Chemical Delivery Systems”Med. Res. Rev., vol. 20, No. 5, pp. 367-416.
Solaja, B. et al. (1996) “A Novelm-CPBA Oxidation:p-Quinols and Epoxyquinols from Phenols”Tetrahedron Letters. vol. 37, No. 21, pp. 3765-3768.
Beers, M.H. and R. Berkow, Editors, The Merck Manual of diagnosis and therapy, pp. 471-473 and pp. 1942-1944 (1999) Merck Research Laboratories, Whitehouse Station, N.J. USA.
Lupon, P. et al. (1983) “Photooxygenierung von Oestrogenen: Eine Neu 19-Norsteroid-Synthese” Verlagsgesellschaft, Weinheim, DE, vol. 95, No. 9, p. 757.
Sedee, A.G. J. et al. (1983) “A synthesis for p-quinol compounds from phenols fused with other saturated rings”Tetrahedron Letters24(51):5779-5780.
Prokai Katalin
Prokai Laszlo
Simpkins James
Badio Barbara P.
Saliwanchik Lloyd & Saliwanchik
University of Florida Research Foundation Inc.
University of North Texas Health Science Center at Fort Worth
LandOfFree
Steroidal quinols and their use for estrogen replacement... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Steroidal quinols and their use for estrogen replacement..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroidal quinols and their use for estrogen replacement... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805556